(Image source from: Twitter.com/ReutersIndia)
Russia's Sputnik V to be Produced in India:- The Russian Direct Investment Fund (RDIF) along with India's Hetero which happens to be the country's biggest pharmaceutical companies inked a deal to produce over 100 million doses of coronavirus vaccine Sputnik V per year in the country. The production of Sputnik V will start early next year. Murali Krishna Reddy, Director, International Marketing, Hetero Labs issued a statement saying that they are pleased to collaborate with RDIF for Sputnik V which happens to be the most anticipated vaccine for coronavirus.
He said "The collaboration will take us a step further in the battle against coronavirus for 'Make in India' campaign possible which is envisioned by our Prime Minister Narendra Modi". The interim clinical trial results of Sputnik V showed 95 percent efficacy on the 42nd day after the dose of vaccine was given. The third phase of clinical trials are approved and they are happening in India, Belarus, the USA, Venezuela and other countries. More than 1.2 billion doses of Sputnik V vaccine came from over 50 countries.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund said "We are delighted to announce the partnership between RDIF and Hetero that will bring up the production of the safe vaccine Sputnik V for Indians".